Mesenbio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mesenbio is a private, pre-clinical stage biotech developing a scalable production platform for extracellular vesicle (EV) therapeutics. Its core innovation is the FT-01 system, a clonal, immortalized mesenchymal stem cell line designed to eliminate batch-to-batch variability and enable cost-effective, clinical-grade manufacturing of EVs. The company is validating its platform through an internal proof-of-concept program, MEV-N01, for rheumatoid arthritis, while actively seeking partnerships to expand into other therapeutic areas. Mesenbio aims to establish FT-01 as the industry standard for reliable EV production.

Rheumatoid Arthritis

Technology Platform

FT-01: A proprietary, immortalized, clonal mesenchymal stem cell line for the consistent, scalable, and GMP-ready production of extracellular vesicles (EVs).

Opportunities

The large and growing market for extracellular vesicle therapeutics across regenerative medicine, immunology, oncology, and CNS disorders creates a major opportunity for a scalable, consistent production platform.

Mesenbio's FT-01 is positioned to become a foundational, licensing-ready technology for multiple partners, enabling rapid expansion beyond its internal proof-of-concept program.

Risk Factors

Key risks include the evolving regulatory pathway for EV-based products, potential technical challenges in proving the long-term stability and therapeutic equivalence of EVs from an immortalized cell line, and intense competition from other companies developing scalable EV manufacturing solutions.

The pre-revenue, partnership-dependent business model also carries execution and funding risks.

Competitive Landscape

The competitive landscape includes other biotechs developing EV manufacturing platforms using various cell sources (e.g., other immortalized lines, engineered cells) and production methods. Mesenbio competes by emphasizing the combined MSC-derived therapeutic profile with pharmaceutical-grade consistency and scalability. Larger pharma companies are also building internal EV capabilities, creating both competitive and partnership potential.

More companies in Cell & Gene Therapy →More companies in United Kingdom →